CARMA 7: Bone and Renal Outcomes in HIV-Exposed, Uninfected Infants with Perinatal Exposure to Tenofovir – Women's Health Research Institute

WHRI

Primary Contract: Evelyn Maan, Research Manager, 604-875-2000 ext. 2463, emaan@cw.bc.ca

About the Study: Anti-HIV medication has reduced the risk of HIV transmission from mother to child from 25% to less than 1%. However, the effects of some of these anti-HIV medications on the developing fetus have not yet been thoroughly studied. One medication in particular, called “Tenofovir”, can cause some bone and kidney problems for HIV+ adults when taken for a long time, especially with existing bone and kidney diseases. The purpose of CARMA 7 is to investigate how fetal exposure to Tenofovir may affect the bone and kidney health of infants who are born to HIV+ women.

Why is this research important? The use of Tenofovir is becoming far more common in anti-HIV medication regimens because it is so well tolerated. As a result, an increasing number of women are getting pregnant while taking this particular medication (almost 25% of HIV+ pregnancies in BC in 2011). Accordingly, it is very important for the current and future health of infants born to HIV+ women to study the effects of this anti-HIV medication.

Study Status: Recruiting

Who can participate: Infants who do not have HIV, born at term (>35 weeks +2 days) to an HIV+ mother who took anti-HIV medication during her pregnancy, specifically Tenofovir, Abacavir, or Zidovudine (the last two for the control group). Infants have visits for the CARMA-7 study at 1 month, 6 months, and 18 months of age.

Co-Investigators: Dr. Helene Cote, Dr. Deborah Money, Dr. Laura Sauve, Dr. Jason Brophy

Funded by: CIHR, Canadian HIV Trials Network

CARMA 7 Participant Consent Form

CARMA 7: Bone and Renal Outcomes in HIV-Exposed, Uninfected Infants with Perinatal Exposure to Tenofovir

Principal Investigator: Dr. Ariane Alimenti

Primary Contract: Evelyn Maan, Research Manager, 604-875-2000 ext. 2463, emaan@cw.bc.ca

About the Study: Anti-HIV medication has reduced the risk of HIV transmission from mother to child from 25% to less than 1%. However, the effects of some of these anti-HIV medications on the developing fetus have not yet been thoroughly studied. One medication in particular, called “Tenofovir”, can cause some bone and kidney problems for HIV+ adults when taken for a long time, especially with existing bone and kidney diseases. The purpose of CARMA 7 is to investigate how fetal exposure to Tenofovir may affect the bone and kidney health of infants who are born to HIV+ women.

Why is this research important? The use of Tenofovir is becoming far more common in anti-HIV medication regimens because it is so well tolerated. As a result, an increasing number of women are getting pregnant while taking this particular medication (almost 25% of HIV+ pregnancies in BC in 2011). Accordingly, it is very important for the current and future health of infants born to HIV+ women to study the effects of this anti-HIV medication.

Study Status: Recruiting

Who can participate: Infants who do not have HIV, born at term (>35 weeks +2 days) to an HIV+ mother who took anti-HIV medication during her pregnancy, specifically Tenofovir, Abacavir, or Zidovudine (the last two for the control group). Infants have visits for the CARMA-7 study at 1 month, 6 months, and 18 months of age.

Co-Investigators: Dr. Helene Cote, Dr. Deborah Money, Dr. Laura Sauve, Dr. Jason Brophy

Funded by: CIHR, Canadian HIV Trials Network

CARMA 7 Participant Consent Form

The Women’s Health Research Institute would like to acknowledge that we are uninvited guests on the unceded ancestral territories of the xʷməθkwəy̓əm (Musqueam), Skwxwú7mesh (Squamish), Stó:lo, and sel̓íl̓witulh (Tsleil-waututh) Nations.

As a provincial research institute committed to improving the health outcomes of women, including those across the 2SLGBTQIA+ spectrum, we recognize our responsibility in the collective effort towards establishing culturally safe health care systems and services that address health inequities among Indigenous peoples, especially Indigenous women, girls, and Two-spirit peoples.

We encourage all people involved in research to read both the Truth and Reconciliation Commission of Canada: Calls to Action and the In Plain Sight Report, and reflect on ways we can incorporate the recommendations into our work. As we gather in spaces together, we encourage you to reflect on your positionality on these lands and your personal commitments to reconciliation.

Top